Loading
Replimune Group, Inc. Stock: price and insider trades · United States
Replimune Group, Inc.: what insiders have been doing
Replimune Group, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 7 insiders have disclosed 23 filings since 18 October 2025.
All open-market trades in the period are sales: 9 sales worth €1.1M, by 5 insiders, with no purchase on record. One trade stands out by size: a sale of €442k from Patel Sushil, disclosed on 12 August 2026, or 0.042% of market capitalisation.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 23 filings here. Over the whole record (from 2021), the tally stands at no purchases and 62 sales. The 10-K for the year ended 31 March 2026 shows -313.9 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
116
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€12M
62 ops. · all time
Who traded when
BuySaleChristopher Sarchi4 sales
Emily Luisa Hill4 sales
Konstantinos Xynos4 sales
Sushil Patel4 sales
Andrew Schwendenman2 sales
Philip Astley-Sparke1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$10.86
Analyst consensus
6 analysts1.75/5
US$14.00Target US$19.50(+80%)US$24.00
Income statement
EBITDA-US$302.3M
Net income-US$313.9M0.0% margin
Valuation
PER (forward)-6.0x
P/Book8.6x
Beta0.94
Balance sheet & cash
Market capUS$1B
Total debtUS$111.6M
Free Cash Flow-US$284.6M
Debt / Equity106%
Profitability & ownership
ROE-134.3%
ROA-51.3%
% insiders1.6%
% institutions105.8%
Last declaration on 24 August 2026
Declarations116 total
50,000 shares0Common StockSEC:0001104659-26-100437:0
9,256 shares@ US$14.280.011% mcap29.6% of flowCommon StockSEC:0001104659-26-098868:0
11,447 shares@ US$12.970.012% mcap23.4% of flowCommon StockSEC:0001104659-26-095006:0
11,448 shares@ US$12.970.012% mcap33.3% of flowCommon StockSEC:0001104659-26-095008:0
7,632 shares@ US$12.970.0082% mcap69.8% of flowCommon StockSEC:0001104659-26-095003:0
39,341 shares@ US$12.970.042% mcap29.9% of flowCommon StockSEC:0001104659-26-095012:0
50,000 shares0Common StockSEC:0001104659-26-040577:0
50,000 shares0Common StockSEC:0001104659-26-040566:0
251,240 shares0Common StockSEC:0001104659-26-040571:0
36,667 shares0Common StockSEC:0001104659-26-040572:0
50,000 shares0Common StockSEC:0001104659-26-040575:0
50,000 shares0Common StockSEC:0001104659-26-040579:0
6,500 shares@ US$8.0119.4% of flowCommon StockSEC:0001104659-26-039967:0
25,000 shares0Common StockSEC:0001104659-26-018159:0
200,000 shares0Common StockSEC:0001104659-25-123290:0
60,000 shares0Common StockSEC:0001104659-25-123286:0
60,000 shares0Common StockSEC:0001104659-25-123285:0
35,000 shares0Common StockSEC:0001104659-25-123282:0
10,000 shares0Common StockSEC:0001104659-25-123279:0
3,169 shares@ US$1.75100.0% of flowCommon StockSEC:0001104659-25-120332:0
10,000 shares@ US$11.136.5% of flowCommon StockSEC:0001104659-25-118483:0
5,208 shares@ US$9.1017.6% of flowCommon StockSEC:0001104659-25-114124:0
7,248 shares@ US$9.1010.3% of flowCommon StockSEC:0001104659-25-114122:0
9,154 shares@ US$5.3710.9% of flowCommon StockSEC:0001104659-25-080403:0
7,952 shares@ US$8.0610.3% of flowCommon StockSEC:0001104659-25-052145:0
25 of 116 declarations
About Replimune Group, Inc.
Replimune Group, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ under the ticker REPL. Headquartered in Woburn, Massachusetts, United States, it was founded in 2015 with the mission of transforming cancer treatment through a new class of oncolytic immunotherapies. For French-speaking investors, Replimune should be viewed as a clinical-stage growth story rather than a commercial-stage pharmaceutical company: value creation is driven primarily by clinical execution, regulatory milestones, and the eventual conversion of data into approvals.
The company’s core business is the development of genetically engineered oncolytic virus therapies designed to attack tumors and stimulate an anti-cancer immune response. Its lead program is RP1, also known as vusolimogene oderparepvec, which is based on a proprietary herpes simplex virus strain engineered to enhance tumor cell killing and systemic immune activation. Replimune is also advancing RP2, a derivative of RP1, and a broader pipeline of candidates aimed at solid tumors. Competitive positioning in this niche is defined by clinical data quality, tolerability, durability of response, and the ability to secure regulatory approval in highly targeted oncology indications.
Read moreShow less
Strategically, Replimune differentiates itself through a focused platform approach in solid tumors and a combination of virotherapy and immuno-oncology. The company maintains internal development and manufacturing capabilities in the United States, a notable asset for a development-stage biotech that must meet demanding quality and supply standards. SEC filings also indicate a broader operating footprint that includes the United Kingdom, reflecting the international nature of its R&D activities. Historically, the company has built its platform around oncolytic virus science and has gradually expanded into melanoma, skin cancers, and other advanced tumor settings.
Recent developments have centered on RP1 and the FDA process. In 2024, Replimune announced a Biologics License Application for RP1 in combination with nivolumab for advanced melanoma after anti-PD1 failure, and it also received Breakthrough Therapy Designation for that program. Through 2025 and into early 2026, the company continued to present clinical updates at major medical meetings and to advance RP2, while reiterating the typical biotech risks around regulatory review, trial outcomes, manufacturing, and financing. For investors in Europe, the company offers exposure to innovative oncology science, but with the high volatility and binary event risk that are characteristic of late-stage clinical biotechnology.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
